Business Wire

MAVENIR

5.4.2022 06:02:13 CEST | Business Wire | Press release

Share
Airtel and Mavenir Conduct India’s First Open RAN Based 5G NSA Validation

Bharti Airtel (“Airtel”), India’s premier communications solutions provider, announced today to have successfully conducted India’s first Open Radio Access Network (Open RAN) based live 5G network validation in partnership with Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects.

The Mavenir Open Virtualised Radio Access Network (Open vRAN) solution is based on commercial off-the-shelf hardware, and 3500MHz Radio employing open interfaces as defined by O-RAN Alliance. Open vRAN brings network elasticity, eliminates vendor lock-in and enables Airtel to leverage virtualization, and web-scale containerization to support an ‘any cloud’ deployment scenario.

The Open RAN based 5G validation has been conducted in Chandigarh and Mohali, over the 3500 MHz band test spectrum allotted to Airtel by the Department of Telecom, Government of India. Speeds of over 1 Gbps were validated with the equipment deployed and configured in Non-Standalone (NSA) mode and using commercially available 5G mobile devices.

Randeep Sekhon, CTO, Bharti Airtel said, “This is a major milestone for the Open RAN ecosystem in India, and yet another validation of the growing readiness of 5G networks based on open architecture. Airtel is delighted to spearhead the innovation efforts of O-RAN Alliance in India. We look forward to deepening our technology partnership with Mavenir and collaborate to accelerate the deployment of these radio access networks.”

BG Kumar, President Communication Services, Mavenir, said, “We are excited to partner with Airtel on 5G Open RAN journey. This partnership with Airtel has given impetus to Open RAN ecosystem towards faster deployment of Open RAN. Mavenir is committed to the India market with its continued investments towards development of cutting-edge technologies at R&D centers across India.”

Airtel has been a Board member since the beginning of O-RAN Alliance, which now associates a world-wide community of more than 300 telecom operators, vendors and research and academic institutions working in a transparent way to develop a sustainable Open RAN ecosystem. Airtel was the first operator in India to commercially deploy an open virtual RAN solution based on disaggregated and open architecture defined by the O-RAN Alliance. It is committed to furthering open RAN solutions by supporting a number of disruptive and innovative partners, helping them develop solutions capable of addressing the scale and complexity of its network and that of other established operators around the world.

About Mavenir:

Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com

About Airtel:

Headquartered in India, Airtel is a global communications solutions provider with over 480 Mn customers in 16 countries across South Asia and Africa. The company ranks amongst the top three mobile operators globally and its networks cover over two billion people. Airtel is India’s largest integrated communications solutions provider and the second largest mobile operator in Africa. Airtel’s retail portfolio includes high speed 4G/4.5G mobile broadband, Airtel Xstream Fiber that promises speeds up to 1 Gbps with convergence across linear and on-demand entertainment, streaming services spanning music and video, digital payments and financial services. For enterprise customers, Airtel offers a gamut of solutions that includes secure connectivity, cloud and data center services, cyber security, IoT, Ad Tech and cloud-based communication. www.airtel.com

Link:

ClickThru

Social Media:

https://www.facebook.com/Mavenir/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Real Chemistry Announces New Asia Pacific Hub with Acquisition of Spurwing Communications in Singapore7.7.2026 01:00:00 CEST | Press release

Expanded footprint advances the company’s global strategy in key growth region for healthcare and pharma brands Real Chemistry, a global leader in AI- and insights-driven healthcare communications, today announced the acquisition of Spurwing Communications, establishing the company’s first Asia Pacific (APAC) strategic hub in Singapore. This milestone strengthens Real Chemistry’s global strategy and presence in APAC, enhancing its ability to support healthcare organizations. Combining deep market expertise with globally integrated capabilities across analytics, medical communications, advertising and strategic communications, the company is well positioned to deliver more connected, local insight-driven support — ultimately helping clients better reach and engage healthcare professionals, patients and caregivers across the region. “APAC is fast becoming one of the most dynamic and strategically important regions for healthcare innovation and access to life-improving therapies,” said Ka

Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release

- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C

Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release

The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag

Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda

Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release

Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye